Defined Daily Dose (DDD)

The Defined Daily Dose (DDD) is a fixed statistical unit — not a clinical recommendation — that the World Health Organization assigns to each drug for the sole purpose of measuring and comparing drug consumption across populations. WHO defines it as “the assumed average maintenance dose per day for a drug used for its main indication in adults.” Researchers who need to quantify how much of a drug a population is using — without access to, or a need for, individual prescription records — use DDD as the common unit that makes those totals comparable across drugs, institutions, regions, and time periods.

How DDDs are assigned

A DDD is only ever assigned to a drug that already has an ATC (Anatomical Therapeutic Chemical) classification code, and WHO allocates one DDD per ATC code and route of administration — so the same active ingredient can carry different DDDs for, say, an oral versus an injectable formulation. Assignment and maintenance is the job of the WHO Collaborating Centre for Drug Statistics Methodology, based at the Norwegian Institute of Public Health in Oslo, which classifies drugs into the ATC system and establishes their DDDs. A WHO International Working Group for Drug Statistics Methodology provides expert oversight, meeting twice yearly to approve new codes and DDD alterations, and the full ATC/DDD index is reviewed and revised annually.

What a DDD is not

The single most important caveat, and the one WHO itself states most directly: the DDD does not necessarily correspond to the recommended or Prescribed Daily Dose (PDD) for any individual patient. It is an artificial, arbitrarily fixed technical unit, set once per ATC code and then held constant for comparability — not adjusted for age, body weight, renal or hepatic function, disease severity, or any of the factors a clinician actually uses to dose an individual patient. A published academic comparison of prescribed and defined daily doses found the two diverge in both directions depending on drug class, which is exactly what the DDD system expects and tolerates, because it was never designed to represent any single patient’s dose.

How the DDD is used in research

DDD’s value is entirely as a research and surveillance tool, not a bedside one:

• Drug utilization research. Aggregating prescription or dispensing volume in DDDs (commonly expressed as DDD per 1,000 inhabitants per day) lets researchers track consumption trends for a drug or therapeutic class over time within a single system, independent of price changes, formulation changes, or units of packaging.
• Cross-national and cross-institutional comparisons. Because the unit is standardized centrally rather than locally, DDD/1,000-inhabitant-days figures are comparable across health systems and countries in a way that raw prescription counts, revenue, or pill counts are not — the standard method behind most published antimicrobial-stewardship and drug-utilization benchmarking studies.
• Pharmacoepidemiology and comparative effectiveness research. Where individual-level dosing data is unavailable or where a population-level exposure proxy is what the research question actually needs, DDD-based exposure estimates stand in for dose in analyses of prescribing intensity, cost, and utilization trends.

Limitations researchers should account for

Because a DDD is fixed once per ATC code rather than derived from real-world prescribing, it can misrepresent actual drug exposure in populations that are systematically dosed differently from the WHO-assumed adult maintenance dose — pediatric populations, renally impaired patients, or therapeutic areas where clinical practice has shifted since a DDD was last reviewed. A published critique commissioned by the pharmaceutical industry group IFPMA specifically flags this drift risk and argues DDD is best treated as a rough population-level indicator rather than a precise exposure measure. Studies relying on DDD-based utilization data should state this limitation rather than presenting DDD/1,000-inhabitant-days figures as equivalent to a measured average patient dose.

Worked example

A drug-utilization study compares antibiotic consumption across three hospitals with different patient volumes and different brands/formulations in use. Rather than comparing raw prescription counts or units dispensed — not comparable across differing pack sizes and strengths — the researchers convert dispensing data to DDD/1,000 patient-days for each hospital, producing a standardized consumption-intensity figure that is directly comparable regardless of which specific products each hospital stocks.

Counter-example

A clinician uses a patient’s actual prescribed dose to make a treatment decision. The DDD assigned to that drug’s ATC code is not a substitute for that clinical judgment and was never intended as one — using a population-level statistical unit to set or evaluate an individual patient’s dose is precisely the misuse WHO’s own documentation warns against.

Related CASRAI content

See CASRAI’s RCT vs. Observational Study comparison for the study designs where DDD-based exposure measures are most often used, and the Confounding Variable entry for a related methodological concern in observational drug-utilization research that relies on population-level exposure proxies like DDD rather than individually measured dose.

Frequently Asked Questions

Is the Defined Daily Dose the same as the Prescribed Daily Dose?

No, and WHO is explicit about this: the DDD is a fixed technical unit assigned once per drug for comparability, while the Prescribed Daily Dose (PDD) is what a clinician actually prescribes an individual patient, adjusted for that patient’s age, weight, renal function, and disease severity. The two frequently diverge, in both directions, depending on the drug and population.

Who assigns and updates Defined Daily Doses?

The WHO Collaborating Centre for Drug Statistics Methodology, based at the Norwegian Institute of Public Health in Oslo, classifies drugs under the ATC system and establishes their DDDs, with a WHO International Working Group meeting twice yearly to approve new codes and DDD changes. The full index is reviewed and revised annually.